Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2026
Earnings, Q3 FY2026
Strong growth drivers lifted Q3 profit and FY2026 guidance despite pipeline setbacks.
Investor update
Remibrutinib combines strong RMS trial results with $4bn-plus sales potential.
Earnings, Q2 FY2026
Q2 delivered sales growth and strong brand momentum, with full-year guidance reaffirmed.
Earnings, Q1 FY2026
Priority brands delivered robust growth, supporting a positive long-term outlook despite generic headwinds.
Investor presentation
Large patient populations across major diseases highlight ongoing unmet needs in advanced therapies.
AGM 2026
Shareholders approved all proposals amid strong results, dividend growth, and strategic focus.
44th Annual J.P. Morgan Healthcare Conference
Strong pipeline, commercial execution, and innovation drive long-term growth and value.
2025
Earnings, Q4 FY2025
Annual
Achieved 8% sales growth, 40.1% core margin, and record free cash flow, with strong brand momentum.
Status Update
Advancing Global Health, access, and sustainability with innovation, partnerships, and measurable impact.
Investor Update Part 2
Disciplined M&A, robust cash flow, and AI-driven efficiency underpin long-term growth.
Investor Update Part 1
Upgraded growth guidance and a catalyst-rich pipeline drive strong long-term outlook.
Investor Update
Earnings, Q3 FY2025
M&A Announcement
Earnings, Q2 FY2025
Earnings, Q1 FY2025
AGM 2025
43rd Annual J.P. Morgan Healthcare Conference 2025
2024
Earnings, Q4 FY2024
Annual
ESG Update
Status Update
Earnings, Q3 FY2024
Investor Update
Earnings, Q2 FY2024